Cancer Research The Future of Cancer Research: Science and Patient Impact  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waldhauer, I.
Right arrow Articles by Steinle, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waldhauer, I.
Right arrow Articles by Steinle, A.
[Cancer Research 66, 2520-2526, March 1, 2006]
© 2006 American Association for Cancer Research


Priority Reports

Proteolytic Release of Soluble UL16-Binding Protein 2 from Tumor Cells

Inja Waldhauer and Alexander Steinle

Department of Immunology, Institute for Cell Biology, Eberhard-Karls University Tübingen, Tübingen, Germany

Requests for reprints: Alexander Steinle, Department of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, D-72076 Tübingen, Germany. Phone: 49-7071-29-80992; Fax: 49-7071-29-5653; E-mail: alexander.steinle{at}uni-tuebingen.de.

The MHC class I–related ligands of the immunoreceptor NKG2D are frequently expressed by tumor cells and stimulate tumor immunity mediated by CD8 T cells and natural killer (NK) cells. In humans, NKG2D ligands (NKG2DL) are encoded by the MHC-encoded MIC and non–MHC-encoded UL16-binding protein (ULBP) families of proteins. Recently, we and others showed that tumor cells release soluble MICA (sMICA), thereby counteracting NKG2D-mediated tumor immunosurveillance. Here, we now report that ULBP2 molecules are likewise released from tumor cells in a processed soluble form, and that soluble ULBP2 (sULBP2) can be detected in sera of some patients with hematopoietic malignancies. Tumor cell–derived sULBP2 as opposed to cell-bound ULBP2 does not down-regulate NKG2D on NK cells. Unexpectedly, the glycosylphosphatidylinositol-anchored ULBP2 molecules are not released by phospholipases but by the action of metalloproteases. Proteolytic shedding of both NKG2D ligands MICA and ULBP2 by tumor cells was strongly enhanced after phorbol 12-myristate 13-acetate treatment and paralleled by a markedly reduced susceptibility to NKG2D-mediated cytotoxicity. Shedding of MICA and ULBP2 can be blocked by the same inhibitors, suggesting the involvement of related metalloproteases. Thus, our data suggest that reducing NKG2DL surface densities is due to a common cleavage process executed by metalloproteases that promotes escape of tumors from NKG2D-mediated immunosurveillance. (Cancer Res 2006; 66(5): 2520-6)




This article has been cited by other articles:


Home page
Cancer Res.Home page
I. Waldhauer, D. Goehlsdorf, F. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H.-G. Rammensee, and A. Steinle
Tumor-Associated MICA Is Shed by ADAM Proteases
Cancer Res., August 1, 2008; 68(15): 6368 - 6376.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
W. Cao, X. Xi, Z. Wang, L. Dong, Z. Hao, L. Cui, C. Ma, and W. He
Four novel ULBP splice variants are ligands for human NKG2D
Int. Immunol., August 1, 2008; 20(8): 981 - 991.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
B. Le Maux Chansac, D. Misse, C. Richon, I. Vergnon, M. Kubin, J.-C. Soria, A. Moretta, S. Chouaib, and F. Mami-Chouaib
Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway
Int. Immunol., July 1, 2008; 20(7): 801 - 810.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. R. Siemens, N. Hu, A. K. Sheikhi, E. Chung, L. J. Frederiksen, H. Pross, and C. H. Graham
Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide
Cancer Res., June 15, 2008; 68(12): 4746 - 4753.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Clayton, J. P. Mitchell, J. Court, S. Linnane, M. D. Mason, and Z. Tabi
Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
J. Immunol., June 1, 2008; 180(11): 7249 - 7258.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Armeanu, M. Krusch, K. M. Baltz, T. S. Weiss, I. Smirnow, A. Steinle, U. M. Lauer, M. Bitzer, and H. R. Salih
Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma
Clin. Cancer Res., June 1, 2008; 14(11): 3520 - 3528.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al.
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities
Blood, February 1, 2008; 111(3): 1428 - 1436.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Maccalli, D. Nonaka, A. Piris, D. Pende, L. Rivoltini, C. Castelli, and G. Parmiani
NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients
Clin. Cancer Res., December 15, 2007; 13(24): 7459 - 7468.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
G. Porcu-Buisson, M. Lambert, L. Lyonnet, A. Loundou, M. Gamerre, L. Camoin-Jau, F. Dignat-George, S. Caillat-Zucman, and P. Paul
Soluble MHC Class I chain-related molecule serum levels are predictive markers of implantation failure and successful term pregnancies following IVF
Hum. Reprod., August 1, 2007; 22(8): 2261 - 2266.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Cao, X. Xi, Z. Hao, W. Li, Y. Kong, L. Cui, C. Ma, D. Ba, and W. He
RAET1E2, a Soluble Isoform of the UL16-binding Protein RAET1E Produced by Tumor Cells, Inhibits NKG2D-mediated NK Cytotoxicity
J. Biol. Chem., June 29, 2007; 282(26): 18922 - 18928.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
P. Roda-Navarro and H. T. Reyburn
Intercellular protein transfer at the NK cell immune synapse: mechanisms and physiological significance
FASEB J, June 1, 2007; 21(8): 1636 - 1646.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Suciu-Foca, N. Feirt, Q.-Y. Zhang, G. Vlad, Z. Liu, H. Lin, C.-C. Chang, E. K. Ho, A. I. Colovai, H. Kaufman, et al.
Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients
J. Immunol., June 1, 2007; 178(11): 7432 - 7441.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Lopez-Soto, A. Quinones-Lombrana, R. Lopez-Arbesu, C. Lopez-Larrea, and S. Gonzalez
Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor
J. Biol. Chem., October 13, 2006; 281(41): 30419 - 30430.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Spreu, T. Stehle, and A. Steinle
Human Cytomegalovirus-Encoded UL16 Discriminates MIC Molecules by Their {alpha}2 Domains.
J. Immunol., September 1, 2006; 177(5): 3143 - 3149.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer, A. Steinle, M. Weller, and M. A. Friese
TGF-{beta} and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells
Brain, September 1, 2006; 129(9): 2416 - 2425.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.